Table 4.

Proposed criteria for use for dalbavancin

(A) Infection determinants	1. Invasive infection with gram-positive organism that is microbiologically proven or highly suspected based on previous culturesa,b OR 2. Skin and soft tissue infection that would otherwise require an extended course of intravenous antibiotic therapyc,b AND
(B) Drug determinants	3. Allergy/intolerance to standard therapy with vancomycin, daptomycin, ceftaroline or linezolid 4. Drug toxicity or interactions that prohibit use of vancomycin, daptomycin, ceftaroline or linezolid OR
(C) Social determinants	6. Recent or active intravenous drug use—history or active 7. Lack of support at home 8. Homelessness 9. Recent or active alcohol abuse 10. Nonadherence to medical care

^aThis includes: methicillin susceptible S. aureus, methicillin-resistant S. aureus, Streptococcal spp. and vancomycin-susceptible Enterococcus

^bAttention to source control must be made

^cSevere cellulitis, failure of high-level oral antibiotics (i.e., linezolid), contraindication to oral options (i.e., concomitant selective serotonin receptor inhibitor and linezolid) and malabsorption/lack of enteral access